Advancing next generation intravascular imaging: Kaminari Medical closes 3.8M funding round
Kaminari Medical, an innovator in intravascular imaging technology, has successfully closed a € 3.8M funding round to accelerate product development, expand clinical evidence and fuel market entry.
The round consists of investments (€ 2.3 M) from Graduate Entrepreneur, NLC Health Ventures, Libertatis Ergo Holding (Leiden University) and Demcon Investment. The round was completed by an Innovation Credit of € 1.5 M from the Netherlands Enterprise Agency (RVO). This strategic investment will allow Kaminari Medical to accelerate the development of its breakthrough photoacoustics and ultrasound imaging platform, initiate clinical trials, and work up to market introduction.
Advancing Cardiovascular Care with Photoacoustic Imaging
Coronary Artery Disease (CAD), the leading cause of death worldwide is largely driven by lipid-rich plaques that narrow the coronary arteries and can lead to life-threatening events such as heart attacks and acute coronary syndromes (ACS). Currently available diagnostics tools lack the ability to precisely identify high-risk plaques prone to rupture, leaving interventional cardiologists with limited information when deciding the optimal treatment strategy. Kaminari Medical’s patented intravascular imaging technology leverages the power of photoacoustics and ultrasound to provide real-time qualification of plaque composition, particularly lipid-rich plaques that pose the greatest risk of rupture. By delivering a more accurate assessment of coronary arteries, Kaminari Medical’s solution enables physicians to better assess the risk of major cardiovascular events, guide optimal treatment strategy and save lives.
“We are thrilled to be supported by such esteemed investors who share our vision of transforming cardiovascular diagnostics and therapy guidance,” said Jeroen Kodde, CEO of Kaminari Medical. “This funding allows us to expedite the development of our technology, bring it to healthcare providers, and ultimately improve outcomes for millions of patients affected by cardiovascular disease.”
“With this investment we can bring our scientific endeavours to the patient’s bedside: Knowledge valorisation at its finest,” said Professor Ton van der Steen, co-founder of Kaminari Medical and head of the department of Biomedical Engineering of Erasmus Medical Centre.
“We believe Kaminari Medical is uniquely positioned to disrupt the intravascular imaging space with its innovative approach to cardiovascular diagnostics,” said Graduate Entrepreneur representative Filip Cuypers. “Their novel solution will give physicians the tools they need to make procedures safer, more effective, and ultimately save lives. We are excited to support the company in this next stage of growth.”
Kaminari Medical has already garnered strong interest from leading interventional cardiologists and healthcare institutions due to its unique ability to visualize lipid-rich plaques—a major unmet need in cardiovascular care.
“We’re inspired by physicians’ enthusiasm and the growing evidence supporting plaque characterization for accurate coronary artery disease diagnosis and treatment,” said Alessandro Radaelli, Venture Partner at NLC Health Ventures and Ram Siddappa, Investment Manager at LEH, who have been appointed to Kaminari Medical’s Supervisory Board.
Signing of the agreement between Netherlands Enterprise Agency (RVO) and Kaminari Medical
Many thanks to all new and existing investors: NWO take off 2, UNIIQ – Finance for the Future, Erasmus MC, NLC Health Ventures, Demcon Investment Fund, Libertatis Ergo Holding, Graduate Entrepreneur and the Netherlands Enterprise Agency.
Date: October 15, 2024
Source: Kaminari Medical
